Platelet aggregation in whole blood
This assay measures platelet aggregation in whole blood as a decrease in the number of single platelets and is particularly sensitive to platelet micro-aggregate formation. We have used this assay extensively in pre-clinical and early clinical studies to characterise the mode of action of various compounds on platelets.
The advantage of this approach is that the samples can be stabilised using a dedicated fixative, which allows the analysis to be carried out at a later stage, making this assay an effective alternative to LTA.
The samples can be fixed at several time-points providing data on a dynamic aggregation response, similarly to LTA. Alternatively, samples can be fixed at a single time-point offering a high throughput endpoint assay providing dose-response curves for multiple conditions.
Use of whole blood provides the additional advantage of assessing platelet function in the presence of other blood cells. This can be particularly important for detecting potential indirect effects of agents on platelet function.
Quantitation of platelet aggregation and microaggregate formation in whole blood by flow cytometry. Platelets, 15(2): 85-93. DOI: 10.1080/09537100310001645979
Effects on platelet function of an EP3 receptor antagonist used alone and in combination with P2Y12 antagonist both in vitro and ex vivo in human volunteers. Platelets, 24(5): 392-400.
Development of a novel high throughput 96 well plate-based whole blood assay for investigation of platelet function in healthy volunteers and patients with clinically diagnosed bleeding disorders. http://onlinelibrary.wiley.com/doi/10.1111/jth.12284/epdf – page 763
A new approach to measuring platelet aggregation and platelet-leucocyte conjugate formation in a small volume of fixed whole blood.
http://onlinelibrary.wiley.com/doi/10.1111/jth.12993/epdf – page 655